Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|July 11, 2023
High Cost of Chimeric Antigen Receptor T-Cells: Challenges and SolutionsEdward R Scheffer Cliff, Amar H Kelkar, David A Russler-Germain, et al.
Blood Advances|July 19, 2023
Infections following bispecific antibodies in myeloma: a systematic review and meta-analysisGemma Reynolds, Edward R Scheffer Cliff, Ghulam Rehman Mohyuddin, et al.
JAMA Network Open|November 10, 2023
Adverse Event Reporting in Randomized Clinical Trials for Multiple MyelomaMimi Najjar, John McCarron, Edward R Scheffer Cliff, et al.
Journal of Cancer Policy|December 7, 2023
Use of subjective minimizing language at hematology and oncology conferences: A systematic reviewAbdel-Azez Abusamak, Mohammad Abusamak, Mohammed Al-Abbadi, et al.
The Lancet. Haematology|May 30, 2025
Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignanciesPaul J Bröckelmann, Edward R Scheffer Cliff, Gloria Iacoboni, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 2, 2025
Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myelomaTobias Tix, Mohammad Alhomoud, Roni Shouval, et al.
Journal of the National Cancer Institute|March 2, 2024
Dietary interventions in cancer: a systematic review of all randomized controlled trialsNosakhare Paul Ilerhunmwuwa, Abul Hasan Shadali Abdul Khader, Calvin Smith, et al.
JCO Oncology Practice|July 24, 2025
Patient Preferences on Clinical Decision Making in Multiple MyelomaGhulam Rehman Mohyuddin, Rajshekhar Chakraborty, Katherine Berger, et al.
Annals of Internal Medicine|December 4, 2023
Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness AnalysisAmar H Kelkar, Edward R Scheffer Cliff, Caron A Jacobson, et al.
Journal of the National Cancer Institute|November 9, 2025
Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trialsMaria Mainou, Muatassem Alsadhan, Kalliopi Tsapa, et al.
Pageof 4